You are here

Celgene

These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet

These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet

Motley Fool

Flag link:

Biotechs Find Strength In Numbers In Treating Multiple Sclerosis

Biotechs Find Strength In Numbers In Treating Multiple Sclerosis

Investors Business Daily

multiple sclerosis

Flag link:

Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo

Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo

Fierce Pharma

Multiple Myeloma

Flag link:

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

Yahoo/Zacks.com

Gilead Sciences

Flag link:

These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now

These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now

Motley Fool

Bristol-Myers Squibb

Flag link:

What Gilead Could Learn From Celgene

What Gilead Could Learn From Celgene

Seeking Alpha

Gilead Sciences

Flag link:

What the FDA's Hold on Three Merck Studies Means for Other Drug Makers

What the FDA's Hold on Three Merck Studies Means for Other Drug Makers

TheStreet.com

clinical trials

Multiple Myeloma

Bristol-Myers Squibb

Flag link:

Billions of Dollars on the Line for Celgene With These 3 Small Biotechs

Billions of Dollars on the Line for Celgene With These 3 Small Biotechs

Motley Fool

Juno Therapeutics

Flag link:

Prescribed Reading: I/O is the only game in town

Prescribed Reading: I/O is the only game in town

BioPharma Dive

immuno-oncology

Endo International

Vertex Pharmaceuticals

Bristol-Myers Squibb

Flag link:

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

Endpoints

Flag link:

Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?

Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?

Investors Business Daily

Juno Therapeutics

immuno-oncology

Flag link:

Bluebird Bio: Too Much Good News?

Bluebird Bio: Too Much Good News?

Barron's

Flag link:

Angry cancer patient sues Celgene over 500% jump in Revlimid cost

Angry cancer patient sues Celgene over 500% jump in Revlimid cost

Fierce Pharma

Flag link:

Celgene’s oral lupus candidate shows ‘trend to improvement’ in small test

Celgene’s oral lupus candidate shows ‘trend to improvement’ in small test

Fierce Biotech

clinical trials

Flag link:

Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech

Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech

Endpoints

Dragonfly Therapeutics

immuno-oncology

Flag link:

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

Endpoints

Multiple Myeloma

Flag link:

Celgene touts ozanimod MS data, but disability benefit weak over rival med

Celgene touts ozanimod MS data, but disability benefit weak over rival med

Fierce Biotech

multiple sclerosis

Flag link:

Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms

Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms

Fierce Biotech

Vertex Pharmaceuticals

Flag link:

OncoMed racks up three straight clinical disasters as lead drug implodes

OncoMed racks up three straight clinical disasters as lead drug implodes

Endpoints

clinical trials

non-small cell lung cancer

Flag link: